Abolis Biotechnologies has secured €35 million in a funding round led by international investors, including Evonik Venture Capital and L'Oréal's venture fund, BOLD. This investment will enable the company to scale its biomanufacturing operations, accelerate research and development, and expand its Microbiome Studio, which focuses on microbial ecosystems.

A new strategic partnership with L’Oréal and Evonik aims to bring innovative solutions to the healthcare, cosmetics, and chemical sectors. By leveraging Abolis' expertise in strain development and metabolic engineering alongside Evonik's fermentation processes, this collaboration will enhance market offerings.

Since its establishment in 2014, Abolis has raised a total of €1.1 million and achieved significant growth through strategic partnerships. This latest funding marks a pivotal phase in the company's development, allowing it to expand its manufacturing capabilities and better serve its growing customer base.